Overview

Generic Injectables Market is poised to register a CAGR of 12.3% during the forecast period 2022 to 2028.

The rising frequency of chronic illnesses has resulted in investments in generic injectables innovation. The increased popularity of intravenous (IV) or intramascular (IM) medication delivery techniques has stemmed from the desire for quick therapeutic choices. Generic injectables are also becoming more widely acknowledged as less expensive therapies when compared to branded counterparts. These considerations are driving increased generic injectable market acceptance rates.
During the peak of the coronavirus outbreak in India's second wave, there was an extraordinary demand for Remdesivir, an antiviral medicine used to treat patients. Due to Remdesivir's scarcity, firms in the generic injectables market, such as Hetero Medications, an Indian pharmaceutical company and one of the world's leading producers of anti-retroviral drugs, launched Covifor, a generic version of Remdesivir.

Syringes are among the most difficult to examine containers. With the world's largest immunisation campaign in history, the issues posed by syringe inspection become increasingly pertinent when considering the increasing use of injectable medications. These results have resulted in the necessity for advanced inspection techniques to assist producers in dealing with not just the coronavirus pandemic but also a variety of other ailments.

While other containers, such as cartridges, vials, and ampoules, can enter the inspection process independently, syringes are normally transported by conveyor and then flipped upside down. As a result, strong inspection methods are required so that any concealed particles in the funnel can sink down into the liquid, increasing inspection detectability.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Generic Injectables Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Generic Injectables Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Generic Injectables Market:
• Pfizer Inc.
• Novartis AG (Sandoz International GmbH)
• Baxter
• Fresenius SE & Co. KGaA
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC.
• Lupin Ltd.
• Sanofi
• Biocon
(Note: The list of the major players will be updated with the latest market scenario and trends)

Generic Injectables Market Segmentation:
By Product Type
• Large Molecule Injectables:
  o mAb
  o Insulin
  o Others
• Small Molecule Injectables

By Container Type
• Vials
• Ampoules
• Premix
• Prefilled syringes
• Others

By Application
• Oncology
• Infectious diseases
• Cardiology
• Diabetes
• Immunology
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Generic Injectables Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Generic Injectables Market By Product Type, By Container Type, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

 Regional Analysis:

The Asia Pacific region is anticipated to lead the market during the forecast period owing to the increased demand of these injectables with the rising incidences of infectious diseases like typhoid, diarrhoea, cholera, malaria and cancers, high insistence for cheaper medical alternatives and a strong presence of key market players in the region. The North America region, on the other hand, is anticipated to proliferate the market during the forecasted timeframe owing to the approval of novel generic injectables and increasing insistence for cheaper biosimilar products along with increased occurrence of lifestyle-oriented diseases.Pfizer Inc. dominates the global market with over one tenth of the overall market share. Currently, the company is preparing the procedure of developing a formula PF-06881894 which is a biosimilar to Neulasta and which can be used by oncology practitioners. 

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Generic Injectables Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Generic Injectables Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Generic Injectables Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Generic Injectables Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Large Molecule Injectables:
        7.1.1. mAb
        7.1.2. Insulin
        7.1.3. Others
   7.2. Small Molecule Injectables

8. Generic Injectables Market, By Container Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Vials
   8.2. Ampoules
   8.3. Premix
   8.4. Prefilled syringes
   8.5. Others

9. Generic Injectables Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Oncology
   9.2. Infectious diseases
   9.3. Cardiology
   9.4. Diabetes
   9.5. Immunology
   9.6. Others

10. North America Generic Injectables Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Generic Injectables Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Generic Injectables Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Generic Injectables Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Pfizer Inc.
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Novartis AG (Sandoz International GmbH)
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Baxter
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Fresenius SE & Co. KGaA
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Mylan N.V.
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Teva Pharmaceutical Industries Ltd.
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview      
    16.7. Hikma Pharmaceuticals PLC.
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Lupin Ltd.
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Sanofi
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview 
    16.10.Biocon
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview 

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by Baxterinistrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures